ProShares Ultra Bloomberg Natural Gas

United States Natural Gas

GraniteShares 1.5x Short NVDA Daily ETF

Direxion Daily S&P Biotech Bull 3X ETF

MicroSectors Gold Miners 3X Leveraged ETN

Global X Uranium ETF

Direxion Dly S&P Oil&Gs Ex&Prd Bl 3X ETF

Direxion Daily Gold Miners Bull 3X ETF

Direxion Daily 20+ Yr Trsy Bull 3X ETF

ProShares UltraShort Bloomberg Natrl Gas

GraniteShares 1.5x Long Coinbase Daily ETF

Direxion Daily S&P Biotech Bear 3X ETF

GraniteShares 1.5x Long NVDA Daily ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

United States Oil Fund

Direxion Daily 20+ Yr Trsy Bear 3X ETF

Volatility Shares Trust 2x Bitcoin Strategy ETF

Direxion Daily Gold Miners Bear 3X ETF

Easterly Government Properties Inc. Common Stock

AGM Group Holdings Inc. Class A Ordinary Shares

Petros Pharmaceuticals Inc. Common Stock

Pony AI Inc. American Depositary Shares

Portage Biotech Inc. Common Stock

Plug Power Inc. Common Stock

Leggett & Platt Incorporated Common Stock

Altisource Portfolio Solutions S.A. Common Stock

Noble Corporation plc A Ordinary Shares

NIO Inc. American depositary shares each  representing one Class A ordinary share

Spire Global Inc. Class A Common Stock

Ecopetrol S.A. American Depositary Shares

NXP Semiconductors N.V. Common Stock

Tiziana Life Sciences Ltd. Common Shares

MicroFinancial Inc.

TTEC Holdings Inc. Common Stock

PENN Entertainment Inc. Common Stock

Check-Cap Ltd. Ordinary Share

Bioventus Inc. Class A Common Stock

Canaan Inc. American Depositary Shares

Click here to get full coverage on Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? - Yahoo Finance

Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?  Yahoo Finance

Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? - Yahoo Finance

Click here to get full coverage on Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation - simplywall.st

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation  simplywall.st

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation - simplywall.st

Click here to get full coverage on Janux Therapeutics: What's My Inflection Point? (NASDAQ:JANX) - Seeking Alpha

Janux Therapeutics: What's My Inflection Point? (NASDAQ:JANX)  Seeking Alpha

Janux Therapeutics: What's My Inflection Point? (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC - Business Wire

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC  Business Wire

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC - Business Wire

Click here to get full coverage on JANX Stock Price and Chart — NASDAQ:JANX - TradingView

JANX Stock Price and Chart — NASDAQ:JANX  TradingView

JANX Stock Price and Chart — NASDAQ:JANX - TradingView

Click here to get full coverage on JANUX THERAPEUTICS Earnings Preview: Recent $JANX Insider Trading, Hedge Fund Activity, and More - Nasdaq

JANUX THERAPEUTICS Earnings Preview: Recent $JANX Insider Trading, Hedge Fund Activity, and More  Nasdaq

JANUX THERAPEUTICS Earnings Preview: Recent $JANX Insider Trading, Hedge Fund Activity, and More - Nasdaq

Click here to get full coverage on Janux Therapeutics Raises Massive $402.5M in Oversubscribed Public Offering - Stock Titan

Janux Therapeutics Raises Massive $402.5M in Oversubscribed Public Offering  Stock Titan

Janux Therapeutics Raises Massive $402.5M in Oversubscribed Public Offering - Stock Titan

Click here to get full coverage on Long Term Trading Analysis for (JANX) - news.stocktradersdaily.com

Long Term Trading Analysis for (JANX)  news.stocktradersdaily.com

Long Term Trading Analysis for (JANX) - news.stocktradersdaily.com

Click here to get full coverage on Vir Biotechnology (VIR) Trades Higher in Sympathy with Janux Therapeutics (JANX) - StreetInsider

Vir Biotechnology (VIR) Trades Higher in Sympathy with Janux Therapeutics (JANX)  StreetInsider

Vir Biotechnology (VIR) Trades Higher in Sympathy with Janux Therapeutics (JANX) - StreetInsider

Click here to get full coverage on JANX stock touches 52-week low at $29.62 amid market shifts - Investing.com

JANX stock touches 52-week low at $29.62 amid market shifts  Investing.com

JANX stock touches 52-week low at $29.62 amid market shifts - Investing.com

Click here to get full coverage on Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently - Yahoo Finance

Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently  Yahoo Finance

Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently - Yahoo Finance

Click here to get full coverage on Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer - Business Wire

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer  Business Wire

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer - Business Wire

Click here to get full coverage on Janux Therapeutics, Inc. (JANX): Among the Oversold Biotech Stocks to Buy Now - Yahoo Finance

Janux Therapeutics, Inc. (JANX): Among the Oversold Biotech Stocks to Buy Now  Yahoo Finance

Janux Therapeutics, Inc. (JANX): Among the Oversold Biotech Stocks to Buy Now - Yahoo Finance

Click here to get full coverage on Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Business Wire

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants  Business Wire

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Business Wire

Click here to get full coverage on Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode? - Yahoo Finance

Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode?  Yahoo Finance

Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode? - Yahoo Finance

Click here to get full coverage on JANX Stock Hits Record High on Prostate Cancer Study Data - Yahoo Finance

JANX Stock Hits Record High on Prostate Cancer Study Data  Yahoo Finance

JANX Stock Hits Record High on Prostate Cancer Study Data - Yahoo Finance

Click here to get full coverage on Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March - Yahoo Finance

Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March  Yahoo Finance

Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March - Yahoo Finance

Click here to get full coverage on Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy? - Yahoo Finance

Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy?  Yahoo Finance

Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy? - Yahoo Finance

Click here to get full coverage on We're Interested To See How Janux Therapeutics (NASDAQ:JANX) Uses Its Cash Hoard To Grow - Yahoo Finance

We're Interested To See How Janux Therapeutics (NASDAQ:JANX) Uses Its Cash Hoard To Grow  Yahoo Finance

We're Interested To See How Janux Therapeutics (NASDAQ:JANX) Uses Its Cash Hoard To Grow - Yahoo Finance

Click here to get full coverage on Janux Therapeutics Insiders Sold US$6.9m Of Shares Suggesting Hesitancy - simplywall.st

Janux Therapeutics Insiders Sold US$6.9m Of Shares Suggesting Hesitancy  simplywall.st

Janux Therapeutics Insiders Sold US$6.9m Of Shares Suggesting Hesitancy - simplywall.st

Click here to get full coverage on Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout (NASDAQ:JANX) - Seeking Alpha

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout (NASDAQ:JANX)  Seeking Alpha

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Business Wire

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights  Business Wire

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Business Wire

Click here to get full coverage on Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies - Business Wire

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies  Business Wire

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies - Business Wire

Click here to get full coverage on Janux Therapeutics: mCRPC TAM And Promising JANX007’s Phase 1 Data (NASDAQ:JANX) - Seeking Alpha

Janux Therapeutics: mCRPC TAM And Promising JANX007’s Phase 1 Data (NASDAQ:JANX)  Seeking Alpha

Janux Therapeutics: mCRPC TAM And Promising JANX007’s Phase 1 Data (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on Why Janux Therapeutics Crushed the Market Today - The Motley Fool

Why Janux Therapeutics Crushed the Market Today  The Motley Fool

Why Janux Therapeutics Crushed the Market Today - The Motley Fool

Click here to get full coverage on Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - Business Wire

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights  Business Wire

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - Business Wire

Click here to get full coverage on Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million - Business Wire

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million  Business Wire

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million - Business Wire

Click here to get full coverage on Janux Therapeutics: Buoyed By Buyout Speculation (NASDAQ:JANX) - Seeking Alpha

Janux Therapeutics: Buoyed By Buyout Speculation (NASDAQ:JANX)  Seeking Alpha

Janux Therapeutics: Buoyed By Buyout Speculation (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause (NASDAQ:JANX) - Seeking Alpha

Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause (NASDAQ:JANX)  Seeking Alpha

Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on Janux, Vir stocks rally on positive data for Janux drug JANX007 (NASDAQ:JANX) - Seeking Alpha

Janux, Vir stocks rally on positive data for Janux drug JANX007 (NASDAQ:JANX)  Seeking Alpha

Janux, Vir stocks rally on positive data for Janux drug JANX007 (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on Janux Therapeutics stock hits 52-week low at $23.72 - Investing.com

Janux Therapeutics stock hits 52-week low at $23.72  Investing.com

Janux Therapeutics stock hits 52-week low at $23.72 - Investing.com

Click here to get full coverage on Insider Sell Alert: Andrew Meyer Sells Shares of Janux Therapeutics Inc (JANX) - GuruFocus

Insider Sell Alert: Andrew Meyer Sells Shares of Janux Therapeutics Inc (JANX)  GuruFocus

Insider Sell Alert: Andrew Meyer Sells Shares of Janux Therapeutics Inc (JANX) - GuruFocus

Click here to get full coverage on Janux Therapeutics Stock Soars on Prostate Cancer Drug Trial Results - Barron's

Janux Therapeutics Stock Soars on Prostate Cancer Drug Trial Results  Barron's

Janux Therapeutics Stock Soars on Prostate Cancer Drug Trial Results - Barron's

Click here to get full coverage on Janux Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - simplywall.st

Janux Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag  simplywall.st

Janux Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - simplywall.st

Click here to get full coverage on Biotech Rockets 49% To Record High On 'Unprecedented' Results - Investor's Business Daily

Biotech Rockets 49% To Record High On 'Unprecedented' Results  Investor's Business Daily

Biotech Rockets 49% To Record High On 'Unprecedented' Results - Investor's Business Daily

Click here to get full coverage on Latham Advises on Janux Therapeutics’ US$350 Million Public Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP

Latham Advises on Janux Therapeutics’ US$350 Million Public Offering of Common Stock and Pre-Funded Warrants  Latham & Watkins LLP

Latham Advises on Janux Therapeutics’ US$350 Million Public Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP

Click here to get full coverage on Janux Therapeutics price target lowered to $41 from $62 at Scotiabank - Yahoo Finance

Janux Therapeutics price target lowered to $41 from $62 at Scotiabank  Yahoo Finance

Janux Therapeutics price target lowered to $41 from $62 at Scotiabank - Yahoo Finance

Click here to get full coverage on Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy (NASDAQ:JANX) - Seeking Alpha

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy (NASDAQ:JANX)  Seeking Alpha

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on Ra capital management buys $25.3 million in Janux therapeutics stock - Investing.com

Ra capital management buys $25.3 million in Janux therapeutics stock  Investing.com

Ra capital management buys $25.3 million in Janux therapeutics stock - Investing.com

Click here to get full coverage on Janux Therapeutics stock hits 52-week low at $28.92 - Investing.com

Janux Therapeutics stock hits 52-week low at $28.92  Investing.com

Janux Therapeutics stock hits 52-week low at $28.92 - Investing.com

Click here to get full coverage on 10 Oversold Biotech Stocks to Buy Now - Insider Monkey

10 Oversold Biotech Stocks to Buy Now  Insider Monkey

10 Oversold Biotech Stocks to Buy Now - Insider Monkey

Click here to get full coverage on 10 Worst High-Risk High-Reward Growth Stocks To Buy - Insider Monkey

10 Worst High-Risk High-Reward Growth Stocks To Buy  Insider Monkey

10 Worst High-Risk High-Reward Growth Stocks To Buy - Insider Monkey

Click here to get full coverage on 12 Best Up and Coming Stocks to Buy According to Wall Street Analysts - Insider Monkey

12 Best Up and Coming Stocks to Buy According to Wall Street Analysts  Insider Monkey

12 Best Up and Coming Stocks to Buy According to Wall Street Analysts - Insider Monkey

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Viking Therapeutics among potential buyout candidates: Oppenheimer - MSN

Viking Therapeutics among potential buyout candidates: Oppenheimer  MSN

Viking Therapeutics among potential buyout candidates: Oppenheimer - MSN

Click here to get full coverage on Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights - Business Wire

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights  Business Wire

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights - Business Wire

Click here to get full coverage on Insider Sell: David Campbell Sells 15,000 Shares of Janux Therap - GuruFocus

Insider Sell: David Campbell Sells 15,000 Shares of Janux Therap  GuruFocus

Insider Sell: David Campbell Sells 15,000 Shares of Janux Therap - GuruFocus

Click here to get full coverage on Janux Therapeutics CFO sells over $45 million in company stock - Investing.com

Janux Therapeutics CFO sells over $45 million in company stock  Investing.com

Janux Therapeutics CFO sells over $45 million in company stock - Investing.com

Click here to get full coverage on Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Estimates  Yahoo Finance

Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale - Bloomberg.com

Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale  Bloomberg.com

Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale - Bloomberg.com

Click here to get full coverage on Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors - Yahoo Finance

Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors  Yahoo Finance

Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors - Yahoo Finance

Click here to get full coverage on Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Business Wire

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants  Business Wire

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Business Wire

Click here to get full coverage on Janux Therapeutics Announces Proposed Public Offering of Common Stock - Business Wire

Janux Therapeutics Announces Proposed Public Offering of Common Stock  Business Wire

Janux Therapeutics Announces Proposed Public Offering of Common Stock - Business Wire

Click here to get full coverage on Janux Therapeutics (JANX) - Zacks Investment Research

Janux Therapeutics (JANX)  Zacks Investment Research

Janux Therapeutics Inc (JANX)

Price Chart

Key Statistics

Technicals

About JANX

Latest News

Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? - Yahoo Finance

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation - simplywall.st

Janux Therapeutics: What's My Inflection Point? (NASDAQ:JANX) - Seeking Alpha

Advanced Charts

Top Gainers

Top Losers